Skip to main content

Case Series Demonstrates Cannabis’ Effectiveness At Treating Borderline Personality Disorder

Hemp Leaf Hemp Plant Cannabis Sativa

Borderline personality disorder is a serious mental health condition that significantly impacts the way sufferers think and feel about themselves and the world around them. Examples of the negative impact that the condition can have include self-esteem issues, difficulty managing feelings and actions, and a pattern of being involved in unstable relationships.

Borderline personality disorder can involve a big fear of abandonment, and patients may have difficulty being alone, which can be particularly difficult given the fact that the condition often results in people not wanting to be around the patient due to their condition.

The condition usually starts during early adulthood, although a diagnosis could happen at any time during the person’s life. Fortunately, a growing body of evidence is demonstrating that the cannabis plant may be able to help treat the condition.

Below is more information about a recent study from the United Kingdom which presents a recent example of the promising area of research per a news release from NORML:

London, United Kingdom: The use of cannabis products containing THC and CBD are safe and effective in mitigating symptoms in patients diagnosed with emotionally unstable personality disorder (EUPD), according to a case series reported in the journal Brain Sciences. Emotionally unstable personality disorder (a/k/a borderline personality disorder) is a common mental health disorder associated with a range of chronic and debilitating symptoms, including impaired social functioning, unstable mood, and risky, impulsive, or self-injurious behavior.

An international team of researchers assessed the use of cannabis products in a cohort of seven EUPD patients. Subjects consumed products containing both THC and CBD in varying ratios for one month.

Six of the seven participants reported “an improvement in symptoms,” and “none of the participants reported any adverse side effects.”

The study’s authors concluded: “To our knowledge, this case series represents the first medical evidence of the use of CBMPs [cannabis-based medicinal products] for the clinical management of patients with a diagnosis of EUPD. …  [O]ur results suggest that, when deployed in a rigorously controlled clinical environment, CBMPs can provide substantial improvement in symptoms associated with EUPD thus warranting the need for further research on this therapeutic strategy.”

Full text of the study, “Cannabis based medicinal products in the management of emotionally unstable personality disorder: A narrative review and case series,” appears in Brain Sciences.

Canada